A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab

Recruiting now

Conditions studied: Alzheimer's Disease

In brief

The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.

Key facts

Study ID

NCT06322667

Run by

Eisai Co., Ltd.

People needed

5000

Starts

2024-02-14

Expected to finish

2027-12-31

Last updated by the study team

2026-01-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All participants who are treated with lecanemab in routine clinical practice

You may not qualify if…

• None

Where it is running

• Eisai trial site 2 — Hiroshima, Japan (enrolling)
• Eisai trial site 3 — Kyoto, Japan (enrolling)
• Eisai trial site 1 — Tokyo, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.